Dextrose Solutions (5%, 50%)

Dextrose solutions are sterile preparations of glucose (dextrose) in water used in equine medicine to treat hypoglycemia, provide caloric support, and serve as a vehicle for intravenous fluid therapy. Dextrose is the D-isomer of glucose, the primary energy substrate for cells throughout the body. These solutions are available in various concentrations, with 5% dextrose in water (D5W) being isotonic and suitable for routine fluid therapy, while 50% dextrose is a hypertonic solution used for rapid correction of hypoglycemia or caloric supplementation. Dextrose solutions are fundamental components of equine critical care and supportive therapy.

The mechanism of action of dextrose involves providing exogenous glucose to raise blood glucose concentrations and supply cellular energy. Once administered intravenously, dextrose is rapidly distributed throughout the body and enters cells via glucose transporters, where it undergoes glycolysis to produce adenosine triphosphate (ATP), the cellular energy currency. In hypoglycemic states, dextrose supplementation restores normal blood glucose levels and prevents the neurological and systemic consequences of glucose deprivation. Additionally, dextrose provides calories for horses that cannot maintain adequate nutrition through normal feed intake.

Dextrose solutions are available in several concentrations for different clinical applications. Five percent dextrose in water (D5W) contains 50 grams of dextrose per liter and is approximately isotonic when initially administered, though the dextrose is rapidly metabolized leaving free water. This solution provides modest caloric support and is often used as a maintenance fluid or diluent. Higher concentrations including 10%, 25%, and 50% dextrose solutions provide greater caloric density; 50% dextrose (500 grams per liter) is used for bolus treatment of severe hypoglycemia and for concentrated caloric supplementation.

The safety profile of dextrose solutions depends on the concentration and rate of administration. Isotonic 5% dextrose is generally well-tolerated, though rapid administration of large volumes can cause hyperglycemia and osmotic diuresis. Hypertonic dextrose solutions (25% and 50%) require careful administration through appropriate intravenous access, as extravasation causes severe tissue damage. Excessive glucose administration can overwhelm the body's regulatory mechanisms, causing hyperglycemia, glucosuria, and potentially contributing to laminitis in susceptible horses. Veterinary supervision ensures appropriate use of dextrose solutions based on the clinical situation and patient needs.

The primary indication for dextrose solutions in horses is the treatment of hypoglycemia, a metabolic condition characterized by abnormally low blood glucose levels. Hypoglycemia in horses is relatively uncommon in healthy adults but occurs in several clinical contexts, most notably in neonatal foals, horses with hepatic dysfunction, horses that are severely anorexic, and horses with certain metabolic derangements. Clinical signs of hypoglycemia include weakness, depression, tremors, ataxia, seizures, and in severe cases, coma and death. Prompt treatment with intravenous dextrose can be life-saving.

Neonatal foal hypoglycemia represents one of the most critical applications for dextrose therapy in equine practice. Newborn foals have limited glycogen stores and depend heavily on adequate colostrum intake and nursing to maintain blood glucose. Foals that are weak, septic, premature, or unable to nurse normally are at high risk for hypoglycemia. Affected foals may present with weakness, inability to stand, decreased suckle reflex, hypothermia, and seizures. Intravenous dextrose supplementation, often as part of a comprehensive supportive care protocol, is essential for the survival of these patients.

Hepatic lipidosis (fatty liver disease) is another important indication for dextrose administration in horses. This condition, most commonly seen in ponies, miniature horses, and donkeys, occurs when negative energy balance triggers excessive fat mobilization that overwhelms the liver's metabolic capacity. Affected animals may develop severe hepatic dysfunction with hypoglycemia as a complication. Dextrose supplementation helps maintain blood glucose levels while the underlying condition is treated and supports hepatic recovery by reducing the drive for continued fat mobilization.

Caloric support for anorexic horses is a common application for dextrose solutions. Horses that cannot or will not eat due to illness, post-surgical complications, severe dental disease, or other conditions require alternative energy sources. While dextrose solutions cannot provide complete nutrition, they offer immediately available calories that can bridge nutritional gaps while the underlying problem is addressed. The caloric content of dextrose (3.4 kcal per gram) means that substantial volumes are needed to provide meaningful caloric support.

Five percent dextrose in water serves additional purposes beyond glucose supplementation. As a nearly isotonic fluid, D5W can be used as a maintenance fluid in certain situations, though its lack of electrolytes limits its utility compared to balanced electrolyte solutions. D5W is commonly used as a diluent for medications that are incompatible with saline solutions. The free water provided as dextrose is metabolized can be useful in certain fluid therapy strategies. However, the specific application should be determined by the treating veterinarian based on the patient's fluid and electrolyte status.

The dosing of dextrose solutions in horses varies widely based on the clinical indication, severity of hypoglycemia, patient size, and ongoing glucose needs. Treatment of acute severe hypoglycemia requires different protocols than maintenance caloric support in anorexic patients. Accurate weight determination is essential, particularly in foals and small equines, where dosing precision is critical. The veterinarian determines appropriate dextrose dosing based on blood glucose measurements, clinical assessment, and patient response.

For treatment of acute hypoglycemia, bolus administration of hypertonic dextrose (25% or 50%) is typically used. Guidelines generally recommend approximately 0.25 to 0.5 grams of dextrose per kilogram of body weight administered as a slow intravenous bolus. For a 500-kilogram adult horse, this translates to roughly 125 to 250 grams of dextrose, or 250 to 500 milliliters of 50% dextrose solution. For foals, precise weight-based dosing is essential. The bolus should be administered slowly over several minutes while monitoring response. Blood glucose should be rechecked after treatment to confirm improvement.

Maintenance dextrose supplementation for horses with ongoing hypoglycemia risk or caloric needs typically involves continuous intravenous infusion of 5% or 10% dextrose solutions. The rate of administration depends on the patient's glucose requirements and fluid needs. Common approaches include adding dextrose to maintenance fluids to achieve the desired concentration, with target blood glucose levels guiding adjustments. Hypoglycemic foals may require continuous dextrose infusion for extended periods until they are nursing normally. Frequent blood glucose monitoring, initially every 1 to 2 hours, guides infusion rate adjustments.

Administration of dextrose solutions requires attention to proper technique and intravenous access. Five percent dextrose is isotonic and can be administered through peripheral veins without significant risk of vessel injury. Hypertonic dextrose solutions (25% and 50%) are highly irritating to veins and tissues; administration through a well-placed, large-bore catheter is recommended, and verification of catheter patency before and during administration is essential. Extravasation of hypertonic dextrose causes severe tissue necrosis and sloughing. If resistance is encountered or swelling is observed at the injection site, administration should stop immediately.

Treatment duration depends on the underlying cause of hypoglycemia and patient response. Single bolus treatment may suffice for acute hypoglycemic episodes with readily correctable causes. Neonatal foals or horses with ongoing metabolic problems may require dextrose supplementation for days until the underlying condition resolves. Weaning from dextrose supplementation should be gradual, with blood glucose monitoring to ensure the patient can maintain normal levels independently. Abrupt discontinuation of dextrose infusion can result in rebound hypoglycemia in some patients.

If a scheduled dextrose infusion is interrupted or delayed, blood glucose should be checked to assess the patient's status before resuming therapy. Never bolus hypertonic dextrose rapidly to make up for missed infusion time, as this can cause dangerous hyperglycemia and osmotic complications. Contact the veterinarian for guidance on adjusting the treatment protocol after interruptions in therapy.

Dextrose solutions are generally well-tolerated when administered appropriately, but potential adverse effects relate primarily to the rate and total amount of glucose administered, as well as issues with intravenous access. Understanding these potential problems enables appropriate monitoring and intervention when necessary.

Common and generally mild side effects of dextrose administration include transient hyperglycemia, which is expected following bolus dosing and typically resolves as insulin is secreted in response. Glucosuria (glucose in urine) may occur when blood glucose exceeds the renal threshold, leading to osmotic diuresis with increased urine output. Mild phlebitis (vein inflammation) may occur at infusion sites, particularly with prolonged administration or higher concentrations. These effects are usually self-limiting and manageable with appropriate monitoring.

Moderate side effects requiring attention include persistent or severe hyperglycemia, which can occur with excessive dextrose administration or in patients with insulin resistance. Sustained hyperglycemia causes osmotic shifts with cellular dehydration, altered electrolyte balance, and continued glucosuria with fluid and electrolyte losses. Electrolyte disturbances, particularly hypokalemia and hypophosphatemia, can result from glucose-induced cellular uptake of these ions. Fluid overload may occur if dextrose solutions are administered too rapidly, particularly in patients with compromised cardiac or renal function.

Serious side effects of dextrose therapy include severe tissue necrosis from extravasation of hypertonic solutions, which can cause extensive local tissue damage, sloughing, and secondary infection. If extravasation is suspected, administration should stop immediately, and veterinary attention is needed for the affected area. In horses, particularly those with metabolic predispositions, excessive or prolonged hyperglycemia may contribute to laminitis, a devastating condition of hoof laminar inflammation. This concern is especially relevant in ponies, horses with equine metabolic syndrome, and horses with a history of laminitis.

Rare side effects and complications include hypersensitivity reactions to solution components, though true allergic reactions to dextrose are exceedingly rare. Contamination of dextrose solutions can lead to catheter-associated bloodstream infections if aseptic technique is not maintained. Rebound hypoglycemia may occur when dextrose infusion is stopped abruptly in patients who have become dependent on exogenous glucose, particularly neonatal foals. Any horse showing unexpected reactions during dextrose therapy, including fever, changes in attitude, signs of discomfort, or swelling at the catheter site, should receive prompt veterinary evaluation.

Dextrose solutions have relatively few absolute contraindications, but certain conditions require caution or modified approaches. Fluid overload or congestive heart failure are relative contraindications for volume expansion with dextrose solutions, as additional fluid volume can exacerbate pulmonary edema and cardiac dysfunction. In these patients, if glucose supplementation is needed, it should be provided in the minimum necessary volume with careful monitoring of cardiovascular status.

Hyperglycemia is a relative contraindication to additional dextrose administration unless the clinical situation specifically requires it. Patients with persistently elevated blood glucose should have the underlying cause investigated and addressed rather than receiving additional exogenous glucose. Horses with insulin resistance, such as those with equine metabolic syndrome, may have impaired glucose tolerance and are at increased risk for prolonged hyperglycemia with its associated complications. These patients require careful monitoring if dextrose administration is necessary.

Horses at high risk for laminitis require careful consideration before receiving dextrose solutions, particularly in large volumes or over extended periods. This includes horses with equine metabolic syndrome, pituitary pars intermedia dysfunction (PPID/Cushing's disease), history of laminitis, or acute illness with systemic inflammatory response. While dextrose may still be necessary in life-threatening hypoglycemia, the potential contribution to laminitis risk should be weighed against the benefits, and glucose levels should be carefully managed.

Certain concurrent conditions and access issues affect dextrose solution use. Severe electrolyte disturbances, particularly hypokalemia and hypophosphatemia, may be worsened by dextrose administration as glucose-insulin shifts drive potassium and phosphate into cells. These electrolytes should be monitored and replaced as needed. Inadequate venous access is a contraindication for hypertonic dextrose; if only peripheral venous access is available and hypertonic dextrose is needed, it should be diluted to reduce the concentration and minimize the risk of vessel damage. Patients with known contaminated catheters or phlebitis should have new access established before continuing dextrose infusion.

Major drug interactions with dextrose solutions primarily involve medications that affect glucose metabolism or are physically incompatible with dextrose-containing fluids. Insulin has a direct pharmacological interaction with dextrose; while these agents are often used together therapeutically (glucose-insulin infusions for hyperkalemia treatment), concurrent use requires careful monitoring to prevent hypoglycemia. Corticosteroids cause hyperglycemia through various mechanisms and may antagonize the body's response to dextrose, requiring higher doses or prolonged supplementation in hypoglycemic patients receiving steroids.

Moderate interactions include the effects of dextrose on electrolyte dynamics. Dextrose administration stimulates insulin release, which promotes cellular uptake of potassium and phosphate, potentially worsening pre-existing hypokalemia or hypophosphatemia. Patients receiving dextrose infusions should have electrolytes monitored and replaced as needed. Beta-2 agonists such as clenbuterol also promote cellular potassium uptake and may have additive effects with dextrose-induced shifts. Thiamine deficiency can be precipitated or worsened by dextrose administration, as thiamine is required for glucose metabolism; patients with suspected thiamine deficiency should receive supplementation before or concurrent with dextrose.

Physical incompatibilities exist between dextrose solutions and various medications. Some drugs precipitate, degrade, or become inactive when mixed with dextrose. Compatibility should be verified before adding medications to dextrose-containing fluids. Common problem combinations include certain aminoglycoside antibiotics, some penicillins, and sodium bicarbonate, though specific compatibility varies by product and concentration. When in doubt, medications should be administered through separate lines or with appropriate line flushing between incompatible drugs.

Competition and drug testing considerations are generally minimal for dextrose solutions, as glucose is a normal physiological substance. However, intravenous administration of any substance may be subject to regulation in competitive contexts. Some governing bodies restrict intravenous therapies within certain timeframes before competition. The FEI, USEF, racing commissions, and breed organizations each have their own rules regarding fluid therapy. While dextrose itself is unlikely to be prohibited, the circumstances of its administration may fall under general rules about veterinary treatment. Trainers should maintain accurate records and verify current regulations apply to their competition discipline.

Monitoring requirements during dextrose therapy are essential for safe and effective treatment. Blood glucose levels should be measured before initiating therapy to confirm hypoglycemia and monitored regularly during treatment, with frequency depending on the clinical situation. Initial monitoring during acute hypoglycemia treatment may be hourly or more frequent; stable patients on maintenance dextrose may be monitored every 4 to 6 hours. Urine glucose may be checked as a rough indicator of hyperglycemia. Electrolytes, particularly potassium and phosphate, should be monitored in patients receiving ongoing dextrose supplementation. Hydration status and cardiovascular parameters require assessment in patients receiving volume as part of dextrose therapy.

Special populations require modified approaches to dextrose administration. Neonatal foals are among the most common recipients of dextrose therapy and require precise weight-based dosing, frequent blood glucose monitoring, and careful attention to fluid balance given their small size. These patients may have immature metabolic regulation and are at risk for both hypo- and hyperglycemia. Geriatric horses may have underlying metabolic conditions including PPID that affect glucose handling. Horses with hepatic dysfunction require careful glucose monitoring, as the liver plays a central role in glucose regulation. Horses with equine metabolic syndrome or insulin resistance need careful consideration of the risks versus benefits of dextrose therapy.

Competition and performance horse considerations apply to dextrose administration. While dextrose is a normal physiological substance, regulations regarding intravenous therapies vary among governing bodies. Some organizations restrict any intravenous treatment within specified timeframes before competition. Record-keeping for all treatments is advisable for competition horses. Consult current rules from FEI, USEF, racing commissions, or breed organizations as applicable to the specific competitive discipline.

Administration precautions are particularly important for hypertonic dextrose solutions. These solutions (25% and 50%) cause severe tissue necrosis if they leak from veins into surrounding tissue (extravasation). Administration should only occur through well-placed, large-bore intravenous catheters with confirmed patency. The injection site should be monitored throughout administration for swelling, which would indicate extravasation. If extravasation occurs, administration should stop immediately and the affected area should receive veterinary attention. Dilution of hypertonic solutions before administration reduces but does not eliminate this risk. Five percent dextrose is much safer for peripheral administration but still requires proper intravenous access.

Long-term dextrose supplementation considerations include the risk of rebound hypoglycemia when therapy is discontinued. Patients who have received prolonged dextrose infusions may have suppressed endogenous glucose production and require gradual weaning with blood glucose monitoring to ensure they can maintain normal levels independently. Prolonged hyperglycemia from excessive dextrose administration may contribute to complications including laminitis. The goal of therapy should be to maintain blood glucose in the normal range while addressing the underlying condition, allowing eventual discontinuation of exogenous glucose support.

Proper storage of dextrose solutions is essential for maintaining sterility and stability. Solutions should be stored at controlled room temperature, typically between 68°F and 77°F (20°C to 25°C), protected from freezing and excessive heat. Exposure to freezing can cause container damage and compromise sterility. Excessive heat may accelerate degradation. Solutions should be stored in their original packaging until ready for use to protect from light exposure. Storage in barn or field environments requires attention to temperature extremes that may occur in tack rooms or vehicles.

Handling and safety practices for dextrose solutions focus on maintaining sterility and preventing complications. Solutions should be inspected visually before use; they should be clear and colorless to faintly yellow without visible particulates or turbidity. Discolored or particulate-containing solutions should not be used. Aseptic technique is essential when accessing containers and preparing solutions for administration to prevent microbial contamination. Dextrose solutions support microbial growth if contaminated, so unused portions of opened containers should generally be discarded according to manufacturer guidelines and institutional protocols, typically within 24 hours.

Expiration and disposal of dextrose solutions must follow appropriate guidelines. All solutions have printed expiration dates that must be observed; expired solutions should not be used, as sterility and stability cannot be guaranteed. Once a container is opened or a bag is punctured, the contents should be used promptly or discarded according to institutional protocols for partially used intravenous solutions. Empty containers may be disposed of according to local regulations for medical waste. Unused or expired solutions should be disposed of according to pharmaceutical waste guidelines, which may include return to a veterinary clinic or pharmacy. Solutions should not be poured down drains without confirming this disposal method is acceptable under local regulations.

Draft horses including Clydesdales, Percherons, Shires, and Belgians present specific considerations for dextrose therapy primarily related to their large body mass. These breeds commonly weigh 1,600 to 2,200 pounds or more, requiring substantially larger volumes of dextrose solution to achieve therapeutic effects. Bolus dosing for hypoglycemia must be calculated based on actual body weight, and maintenance infusions require higher flow rates to provide adequate glucose. Large-bore catheters and appropriate fluid delivery systems are necessary for volume resuscitation in these breeds. Draft horses performing heavy work may have different metabolic demands than lighter breeds.

Light horse breeds and warmbloods represent a large portion of adult horses receiving dextrose therapy, often in the context of illness, surgery, or intensive care. Standard dosing guidelines apply to these breeds, with weights typically ranging from 900 to 1,400 pounds. Athletic horses in these breeds may have different glucose dynamics during and after intense exercise. Horses with breed predispositions to metabolic conditions, including Morgan horses and other easy keepers, should be monitored carefully during dextrose therapy. Competition regulations for performance horses in these breeds require attention if dextrose therapy is administered in proximity to competitive events.

Ponies and miniature horses require particular caution with dextrose therapy due to several factors. These small equines, weighing 150 to 900 pounds, require precise weight-based dosing to prevent both under-treatment and overdose. More importantly, ponies and miniature horses are highly predisposed to hyperlipemia and hepatic lipidosis during periods of negative energy balance. While these conditions may require glucose supplementation, there is also evidence that prolonged hyperglycemia may contribute to laminitis risk in these metabolically sensitive breeds. Blood glucose should be monitored carefully during therapy to maintain levels in the normal range without excessive hyperglycemia. Concurrent monitoring for signs of laminitis is warranted.

Breed-specific sensitivities relevant to dextrose therapy primarily involve metabolic predispositions. Horses with equine metabolic syndrome, which is more common in certain breeds including Morgans, some pony breeds, and Paso Finos, may have insulin resistance that affects their response to glucose loading. These horses are at increased risk for laminitis, and any dextrose therapy should be accompanied by careful monitoring. Arabian horses and related breeds may carry genes for various metabolic conditions, though none specifically contraindicate dextrose use. Friesian horses have metabolic peculiarities including tendency toward metabolic acidosis in ill individuals, which may affect overall fluid therapy strategies including dextrose use. Quarter Horses with HYPP have abnormal potassium handling rather than glucose issues, but the potassium-shifting effects of glucose-insulin dynamics are relevant when managing these patients.

Alternative glucose-containing products in the same therapeutic category include dextrose combined with electrolyte solutions, such as dextrose in saline or dextrose in lactated Ringer's solution. These combination products provide both glucose and electrolyte replacement simultaneously and may be appropriate when both needs exist. Oral glucose or corn syrup can be used for less severe hypoglycemia in conscious patients able to swallow, though absorption is slower and less predictable than intravenous administration. Propylene glycol has been used as an alternative energy source in some species but is not commonly used in horses due to toxicity concerns.

Different class options for nutritional support when dextrose alone is insufficient include parenteral nutrition solutions providing amino acids and lipids in addition to glucose for more complete nutritional support in horses unable to eat. Enteral feeding via nasogastric tube is preferable when gastrointestinal function is adequate, as this route maintains intestinal health and is more physiologically appropriate. Lipid emulsions provide concentrated calories without glucose load and may be useful when hyperglycemia is a concern, though experience in horses is limited. The choice of nutritional support strategy depends on the patient's condition, duration of anticipated support needed, and available resources.

Complementary therapies and management strategies support dextrose therapy and address underlying conditions. Identification and treatment of the cause of hypoglycemia is paramount; dextrose provides supportive care but does not address underlying problems. For neonatal foals, ensuring adequate nursing or providing milk replacer addresses nutritional needs beyond glucose supplementation. For horses with hepatic lipidosis, reducing factors that drove fat mobilization (such as providing adequate feed access and reducing stress) is essential alongside glucose support. Electrolyte monitoring and replacement, particularly potassium and phosphate, should accompany dextrose therapy. Thiamine supplementation may be appropriate for horses receiving prolonged dextrose infusions. Transition from parenteral to enteral nutrition should occur as soon as gastrointestinal function allows. All decisions regarding nutritional support and glucose therapy should be made under veterinary guidance based on the specific clinical situation.